Uncategorized

El almacenamiento de información cuántica en átomos individuales representa una de las fronteras más emocionantes de la ciencia y la tecnología moderna. Este avance promete revolucionar la computación cuántica, las telecomunicaciones y la criptograf&i …

The FDA’s year-end rush includes ten target action dates, mostly for rare disease and cancer therapies.

By speeding lifesaving drugs’ way to market and focusing on the underlying causes of disease, the pathway has helped save many lives.

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

The job cuts in Memphis are part of a turnaround plan that has seen the U.K.-based medical device maker shutter four smaller orthopedics facilities outside the U.S.

The company has generated evidence that shows its system is better than experts at assessing vessel narrowing, plaque volume and composition.

UnitedHealth, Elevance and some BCBS plans have deleted senior leadership pages from their corporate sites, while Centene and CVS scrubbed images of their executives online.

The program has recently become controversial as a number of high-profile advanced approvals were granted only for the drugs to fail a confirmatory trial later on. Now, the FDA has clearly laid out expectations.

It’s the latest provider to be hit with a hefty settlement. Earlier this year, Novant Health and Cerebral paid $6.6 million and more than $7 million, respectively, to settle similar claims.

Brian Thompson’s death on Wednesday set off a flood of darkly celebratory social media posts offset by solemn remembrances from his peers and other healthcare leaders.